Systemic amiloride inhibits experimentally induced neovascularization.
Amiloride is an inhibitor of urokinase-type plasminogen activator, and might therefore have an inhibitory effect on neovascularization. Neovascularization was induced in rabbit corneas via local implantation of prostaglandin E1 pellets prepared in a slow-release polymer. Animals received daily intraperitoneal injections of 30 mg of amiloride, or an equivalent volume of saline solution for 5 days; both were well tolerated without severe untoward effect. Neovascular response, as documented by corneal photographs, was evaluated after 5 days of injections. The area of induced corneal neovascularization was decreased by 55% in animals receiving amiloride when compared with controls. Thus, amiloride and similar compounds may prove useful in the study and management of neovascularization.
Wilmer Ophthalmological Institute, Johns Hopkins Hospital, Baltimore, MD 21205.
R L
RL
Avery
T B
TB
Connor
M
M
Farazdaghi
D000527:Alprostadil; D000584:Amiloride / Q000494:pharmacology*; D000818:Animals; D003315:Cornea / Q000098:blood supply / Q000187:drug effects*; D004195:Disease Models, Animal; D009389:Neovascularization, Pathologic; D010781:Photography; D011817:Rabbits
D000584:Amiloride; D000527:Alprostadil